At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 124 enrolled
Drug / intervention
Lanreotide Autogel 120 mgdrug
Likely dose
Lanreotide Autogel 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, International, Multi-centric, Open-label Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel 120 mg in Acromegalic Subjects Who Are Biochemically Controlled on the Long Term Treatment With Octreotide LAR 10 or 20 mg
In Brief
A Phase 4 clinical trial evaluating Lanreotide Autogel 120 mg for Acromegaly. Completed, enrolled 124 participants across 44 sites in 14 countries.
Detailed Summary
The purpose of the study is to assess the efficacy of an extended injection interval schedule of lanreotide Autogel 120 mg in acromegalic subjects who are biochemically controlled on long term treatment with octreotide LAR 10 or 20 mg
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcromegaly
CountriesBrazil, Denmark, Finland, France, Greece, Latvia, Netherlands, Norway, Poland, Romania, Russia, Serbia, South Korea, Sweden
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2008
Enrollment StartOct 2008
Primary CompletionMar 2013
Study CompletionMay 2013
TodayJul 2026
First PostedJun 19, 2008
Enrollment StartOct 1, 2008
Primary CompletionMar 1, 2013
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 18.0 years ago
Interventions
Lanreotide Autogel 120 mgdrug
120mg, injections every 6 weeks, then depending on IGF-1 results at Week 24